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Abstract A series of some new 2,3-disubstituted-6-iodo-3H-quinazolin-4-one derivatives was pre-
pared and screened for their in vitro antitumor activity against the human breast cancer cell line
(MCF-7), human cervix carcinoma cell line (HeLa), human liver cancer cell line (HepG2) and
human colon cancer cell line HCT-8. Five compounds exhibited broad spectrum antitumor activity,
better than the standard drug Doxorubicin (CAS-23214-92-8) against the four tested cell lines. In
the present study, MCF-7 cell line was the most sensitive one, 12 compounds were good cytotoxic
towards it. The best cytotoxic results were obtained with compounds bearing allyl and/or benzyl
moiety at positions 2 and/or 3 of the quinazoline nucleus.
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Cancer is one of the major challenges which concern the med-
ical community all over the world (Jerry and Woodring,
2006). Most of the antineoplastic agents are designed to inter-
fere with the protein synthesis followed by the inhibition of
cell vital processes leading to cell death (Kano et al., 2010).
Quinazoline-containing compounds represent an attractive
scaffold for designing interesting anticancer drugs (Garofalo
et al., 2010). They have attracted more interest because of* Tel.: +966 507069896.
E-mail addresses: alafeefy@hotmail.com, ahmed.alafeefy@yahoo.
com
1319-6103 ª 2011 King Saud University. Production and hosting by
Elsevier B.V.
Peer review under responsibility of King Saud University.
doi:10.1016/j.jscs.2011.06.019
Production and hosting by Elsevier
Open access under CC BY-NC-ND license.their diverse biological activity notably as kinase inhibitors
(Klutchko et al., 2006; Denny, 2001; Li et al., 2010).
Research on the 4-anilinoquinazoline derivatives has led to
the development and the marketing of a new series of antitu-
mor agents, such as geﬁtinib, erlotinib and lapatinib (Nelson
and Dolder, 2006; Lin et al., 2010; Gridelli et al., 2011). In
recent years research on quinazoline derivatives has led to
the development of several DNA-alkylators that were more
active than kinase inhibitors (Smaill et al., 1999; Sirisoma
et al., 2010; Ryckebusch et al., 2008). Such compounds inter-
act with DNA and present selective recognition of DNA se-
quences (Anthony et al., 2006).
Very recently, certain 6-bromo and/or chloro-quinazoline
derivatives that decreased polyglutamate aggregate burden in
a cell based-assay were identiﬁed from a high-through-put
screen of a chemical compound library. This effort yielded
leads with sub-micro-molar potency (Rinderspacher et al.,
2009).
In the quest for biologically active new small-molecule anti-
tumor agents, we have designed, synthesized and screened some
novel 2,3,6-tri-substituted 3H-quinazolin-4-one derivatives.
The new compounds were designed to contain benzyl, allyl
and/or phenacyl moieties linked to sulfur atom at position-2.Some new quinazolin-4(3H)-one derivatives, synthesis
and antitumor activity
These alkyl substituents are stable good leaving groups and are
expected to be potential alkylators especially when attached to
an electron-rich atom. In the same vein, phenyl and/or benzyl
moieties attached at position-3 and ﬁnally iodine atom which
is not fully investigated at position-6. These derivatives are ex-
pected to be effective double alkylating agents.
2. Materials and methods
2.1. Chemistry
Melting points (C, uncorrected) were determined in open cap-
illaries on a Gallenkamp melting point apparatus (Sanyo
Gallenkamp, Southborough, UK) and were uncorrected. Pre-
coated silica gel plates (silica gel 0.25 mm, 60G F254; Merck,
Germany) were used for thin layer chromatography, dichloro-
methane/methanol (9.5:0.5) mixture was used as a developing
solvent system and the spots were visualized by ultraviolet
light and/or iodine. Infra red spectra were recorded in KBr
discs using IR-470 Shimadzu spectrometer (Shimadzu, Tokyo,
Japan). 1H NMR spectra (in CDCl3) were recorded on Bruker
AC-300 Ultra Shield NMR spectrometer (Bruker, Flawil,
Switzerland, dppm) at 300 MHz for 1H and 125 MHz for
13C, using TMS as internal standard and peak multiplicities
are designed as follows: s, singlet; d, doublet; t, triplet; m, mul-
tiplet. Electron Impact Mass Spectra were recorded on a
Shimadzu GC-MS-QP 5000 instrument (Shimadzu, Tokyo,
Japan). Elemental analyses were performed on Carlo Erba
1108 Elemental Analyzer (Heraeus, Hanau, Germany) and
the results were within 0.4% of theoretical values.
2.2. 6-Iodo-2-mercapto-3-substituted-3H-quinazolin-4-one
(1a–c)
A mixture of 5-iodoanthranilic acid (2.63 g, 0.01 mol), the
appropriate isothiocyanate derivative (0.011 mol) and triethyl-
amine (1 ml) in absolute ethanol (30 ml) was heated under
reﬂux for 3 h. The reaction mixture was left to cool and the sol-
vent was removed under reduced pressure. The obtained solid
was then washed with petroleum ether, dried and crystallized
from ethanol.
2.3. 2-Aroylmethylthio-3-substituted-6-iodo-3H-quinazolin-4-
ones (2–13)
A mixture of 2-mercaptoquinazoline derivative 1a–c
(0.01 mol), the appropriate alkyl halide (0.01 mol) and anhy-
drous potassium carbonate (1 g) in acetone (30 ml) was heated
under reﬂux for 5 h. After cooling, the solvent was removed
under vacuum and the separated solid was ﬁltered, washed
with water, dried and crystallized from ethanol.
Compound 2: IR (KBr, cm1): 3079 (CH aroma.), 2939,
2886 (CH aliph.), 1709, 1676 (2C‚O), 1624 (C‚N). 1H
NMR: d 4.61 (s, 2H, CH2S), 4.70 (d, 2H, CH2N,
J= 7.0 Hz), 5.13–5.17 (d, 2H, ‚CH2, J= 7.5 Hz), 5.88 (m,
1H, ‚CH), 7.20–8.29 (m, 8H, Ar–H). 13C NMR: d 38.5
(CH2S), 44.3 (CH2N), 96.1, 119.4, 125.4, 127.1, 130.4, 135.2,
137.5, 139.2, 144.3, 148.2, 156.8, 164.3, 196.0. MS m/z (Rel.
Int.): 463 (M++1, 0.25), 462 (M+, 1.30), 231 (37.5), 185
(8.8), 105 (100), 77 (38.1).
Compound 3: IR (KBr, cm1): 3082 (CH aroma.), 2935,
2890 (CH aliph.), 1711, 1670 (2C‚O), 1631 (C‚N). 1H
NMR: d 4.08 (s, 2H, CH2N), 4.49 (s, 2H, CH2S), 7.11–8.12
(m, 13H, Ar–H). 13C NMR: d 38.7 (CH2S), 45.2 (CH2N),
96.0, 125.8, 127.3, 130.6, 132.4, 136.1, 139.2, 145.6, 149.0,
156.2, 164.9, 195.8. MS m/z (Rel. Int.): 513 (M++1, 2.85),
512 (M+, 11.66), 303 (11.7), 207 (10.2), 199 (27.7), 185 46.8),
105 (100), 77 (52.8).
Compound 4: IR (KBr, cm1): 3080 (CH aroma.), 2933,
2881 (CH aliph.), 1711, 1670 (2C‚O), 1628 (C‚N). 1H
NMR: d 4.15 (s, 2H, CH2S), 7.12–8.29 (m, 13H, Ar–H).
13C
NMR: d 38.7, 96.3, 125.5, 127.4, 130.0, 132.5, 136.1, 139.2,
145.8, 149.1, 156.7, 165.4, 196.2. MS m/z (Rel. Int.): 498
(m/z M+), 303 (11.8), 199 (25.6), 185 (44.4), 105 (100).
Compound 5: IR (KBr, cm1): 3077 (CH aroma.), 2930,
2884 (CH aliph.), 1710, 1678 (2C‚O), 1635 (C‚N). 1H
NMR: d 4.66 (s, 2H, CH2S), d 4.84 (d, 2H, CH2N,
J= 7.5 Hz), 5.21–5.25 (d, 2H, CH‚CH2, J= 7.0 Hz), 5.99
(m, 1H, ‚CH), 7.25–8.21 (m, 7H, Ar–H). 13C NMR: d 38.2,
44.7, 96.3, 120.3, 125.5, 127.2, 130.8, 134.5, 137.4, 139.3,
145.2, 149.1, 156.8, 163.6, 196.2. MS m/z (Rel. Int.): 543
(M++2, 2.1), 541 (M+, 2.06), 303 (11.4), 199 (22.5), 185
(39.5), 105 (100), 77 (49.6).
Compound 6: IR (KBr, cm1): 3087 (CH aroma.), 2930,
2894 (CH aliph.), 1710, 1680 (2C‚O), 1618 (C‚N). 1H
NMR: d 4.42 (s, 2H, CH2N), d 4.83 (s, 2H, CH2S), 7.25–
8.18 (m, 12H, Ar–H). 13C NMR: d 38.2 (CH2S), 45.6
(CH2N), 96.1, 125.8, 127.3, 128.4, 129.3, 133.5, 137.1, 139.4,
143.6, 145.2, 149.0, 156.3, 165.5, 196.1. MS m/z (Rel. Int.):
593 (M++2, 3.0), 591 (M+, 3.11), 388 (10.9), 297 (11.6),
295 (10.2), 263 (19.7), 91 (100).
Compound 7: IR (KBr, cm1): 3085 (CH aroma.), 2940,
2895 (CH aliph.), 1710, 1682 (2C‚O), 1633 (C‚N). 1H
NMR: d 4.12 (s, 2H, CH2S), 7.11–8.23 (m, 12H, Ar–H).
13C
NMR: d 39.0, 96.3, 125.4, 126.8, 130.5, 132.5, 134.1, 136.7,
139.4, 145.1, 149.5, 164.3, 166.1, 196.0. MS m/z (Rel. Int.):
579 (M++2, 1.83), 577 (M+, 1.80), 289, (75.3), 287 (75.2),
281 (46.1), 207 (86.8), 73 (100).
Compound 8: IR (KBr, cm1): 3089 (CH aroma.), 2943,
2895 (CH aliph.), 1712, 1685 (2C‚O), 1627 (C‚N). 1H
NMR: d 4.69 (s, 2H, CH2S), d 4.85 (d, 2H, CH2N,
J= 7.0 Hz), 5.21–5.25 (d, 2H, CH‚CH2, J= 7.5 Hz), 5.99
(m, 1H, ‚CH), 7.25–8.21 (m, 7H, Ar–H). 13C NMR: d 38.7,
44.2, 96.0, 119.4, 125.1, 127.2, 130.6, 133.2, 137.4, 139.3,
142.5, 145.1, 149.0, 156.4, 164.2, 197.0. MS m/z (Rel. Int.):
498 (M++2, 1.14), 496 (M+, 3.26), 288 (19.2), 286 (57.3),
281 (16.9), 207 (45.7), 160 (86.7), 133 (100).
Compound 9: IR (KBr, cm1): 3090 (CH aroma.), 2935,
2890 (CH aliph.), 1711, 1683 (2C‚O), 1615 (C‚N). 1H
NMR: d 4.33 (s, 2H, CH2S), d 4.75 (s, 2H, CH2N), 7.11–
8.18 (m, 12H, Ar–H). 13C NMR: d 38.2 (CH2S), 45.8
(CH2N), 96.5, 125.2, 127.4, 130.5, 131.5, 133.4, 136.2, 138.6,
141.0, 144.2, 145.1, 149.6, 156.1, 165.3, 196.2. MS m/z (Rel.
Int.): 548 (M++2, 4.71), 546 (M+, 13.60), 289, (78.1), 287
(88.9), 281 (49.3), 207 (85.4), 73 (100).
Compound 10: IR (KBr, cm1): 3082 (CH aroma.), 2945,
2892 (CH aliph.), 1711, 1680 (2C‚O), 1624 (C‚N). 1H
NMR: d 4.04 (s, 2H, CH2S), 7.12–8.20 (m, 12H, Ar–H).
13C
NMR: d 39.0 (CH2S), 96.1, 124.5, 126.3, 128.0, 131.6, 134.2,
137.3, 139.2, 143.9, 145.0, 149.1, 164.5, 166.2, 195.7. MS m/z
(Rel. Int.): 534 (M++2, 0.86), 532 (M+, 2.59), 289, (75.1),
287 (88.5), 281 (49.5), 207 (86.1), 73 (100).
Compound 11: IR (KBr, cm1): 3083 (CH aroma.), 2985,
2892 (CH aliph.), 1710, 1684 (2C‚O), 1638 (C‚N). 1H
NMR: d 4.54 (s, 2H, CH2S), d 4.91 (d, 2H, CH2N,
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J= 7.0 Hz), 5.11, 5.18 (d, 2H, CH‚CH2, J= 7.0 Hz), 5.88
(m, 1H, ‚CH), 7.25–8.28 (m, 7H, Ar–H). 13C NMR: d 38.6
(CH2S), 44.1 (CH2N), 96.4, 120.2, 125.3, 127.5, 131.3, 136.4,
138.3, 145.0, 148.5, 155.2, 157.5, 164.3, 165.4, 197.0. MS m/z
(Rel. Int.): 508 (M++1, 1.6), 507 (M+, 7.5), 327 (18.5), 232
(15.2), 160 (100).
Compound 12: IR (KBr, cm1): 3092 (CH aroma.), 2977,
2899 (CH aliph.), 1710, 1684 (2C‚O), 1630 (C‚N). 1H
NMR: d 4.27 (s, 2H, CH2N), d 4.88 (s, 2H, CH2S), 7.13–
8.20 (m, 12H, Ar–H). 13C NMR: d 38.4 (CH2S), 45.3
(CH2N), 96.2, 125.6, 127.2, 129.1, 131.3, 133.5, 139.1, 144.5,
145.4, 148.3, 155.8, 156.3, 164.1, 197.0. MS m/z (Rel. Int.):
558 (M++1, 3.5), 557 (M+, 18.0), 289, (73.9), 287 (87.8),
281 (47.6), 207 (83.6), 73 (100).
Compound 13: IR (KBr, cm1): 3096 (CH aroma.), 2978,
2881 (CH aliph.), 1712, 1685 (2C‚O), 1619 (C‚N). 1H
NMR: d 3.95 (s, 2H, CH2S), 7.23–8.27 (m, 12H, Ar–H).
13C
NMR: d 38.8, 97.1, 124.3, 125.4, 128.1, 130.6, 131.5, 135.3,
138.0, 145.2, 148.5, 155.1, 163.4, 165.3, 196.8. MS m/z: 544
(M++1, 6.15), 543 (M+, 34.0), 289, (57.8), 287 (80.5), 281
(41.3), 207 (88.8), 91 (100).
2.4. 2-Alkylthio-3-substituted-6-iodo-3H-quinazolin-4-ones (14–
19)
A mixture of 2-mercaptoquinazoline derivative 1a–c
(0.01 mol), the appropriate alkyl halide (0.01 mol) and anhy-
drous potassium carbonate (1 g) in n-butanol (30 ml) was
heated under reﬂux for 24 h. After cooling, the solvent was re-
moved under vacuum and the separated solid was ﬁltered,
washed with water, dried and crystallized from ethanol.
Compound 14: IR (KBr, cm1): 3095 (CH aroma.), 2976,
2891 (CH aliph.), 1684 (C‚O), 1636 (C‚N). 1H NMR: d
3.49 (d, 2H, CH2S, J= 7.0 Hz), 3.90 (d, 2H, CH2N,
J= 7.0 Hz), 5.11–5.17 (m, 4H, 2CH2), 5.83–5.92 (m, 2H,
2CH), 7.25–8.28 (m, 3H, Ar–H). 13C NMR: d 33.8, 45.3,
97.4, 119.5, 120.3, 121.5, 126.1, 128.8, 135.5, 136.2, 138.8,
140.5, 146.0, 150.4, 157.1, 165.7. MS m/z (Rel. Int.): 385
(M++1, 2.5), 384 (M+, 8.7), 356 (7.8), 342 (5.1), 281 (21.6),
207 (87.26), 73 (100).
Compound 15: IR (KBr, cm1): 3095 (CH aroma.), 2969,
2878 (CH aliph.), 1677 (C‚O), 1640 (C‚N). 1H NMR: d
3.88 (s, 2H, CH2S), 4.34 (d, 2H, CH2N, J= 7.0 Hz), 5.12–
5.16 (d, 2H, CH2, J= 7.0 Hz), 5.86–5.90 (m, 1H, CH), 7.25–
8.31 (m, 8H, Ar–H). 13C NMR: d 40.1 (CH2S), 45.9 (CH2N),
97.2, 121.0, 125.5, 126.3, 129.6, 131.4, 137.5, 140.2, 143.8,
146.5, 150.3, 166.0. MS m/z (Rel. Int.): 435 (M++1, 1.3),
434 (M+, 4.9), 433 (27), 281 (41.3), 207 (88.8), 91 (100).
Compound 16: IR (KBr, cm1): 3094 (CH aroma.), 2970,
2872 (CH aliph.), 1681 (C‚O), 1638 (C‚N). 1H NMR: d
3.58 (d, 2H, CH2S, J= 7.0 Hz), 4.65 (s, 2H, CH2N), 5.11–
5.15 (d, 2H, CH2, J= 7.5 Hz) 5.88–5.90 (m, 1H, CH), 7.31–
8.24 (m, 8H, Ar–H). 13C NMR: d 34.2 (CH2S), 45.7 (CH2N),
96.5, 120.1, 125.5, 127.2, 129.5 132.6, 136.2, 140.0, 144.3,
149.1, 156.4, 164.7. MS m/z (Rel. Int.): 435 (M++1, 1.8),
434 (M+, 10.15), 288 (16.5), 286 (67.1), 281 (10.6), 207
(34.4), 160 (84.6), 133 (100).
Compound 17: IR (KBr, cm1): 3097 (CH aroma.), 2890,
2856 (CH aliph.), 1680 (C‚O), 1615 (C‚N). 1H NMR: d
3.84 (s, 2H, CH2S), 4.44 (s, 2H, CH2N), 7.18–8.28 (m, 13H,
Ar–H). 13C NMR: d 40.7, 44.2, 96.0, 125.5, 127.2, 130.8,
131.4, 133.7, 138.3, 142.5, 144.0, 145.1, 148.5, 156.2, 164.2.
MS m/z (Rel. Int.): 485 (M++1, 5.2), 484 (M+, 23.9), 293
(22.2), 292 (19.6), 291 (100), 277 (36.4), 276 (40.5).
Compound 18: IR (KBr, cm1): 3090 (CH aroma.), 2885,
2857 (CH aliph.), 1683 (C‚O), 1635 (C‚N). 1H NMR: d
3.70 (d, 2H, CH2S, J= 7.0 Hz), 5.06–5.13 (d, 2H, ‚CH2,
J= 7.0 Hz), 5.88–5.93 (m, 1H, ‚CH) 7.16–8.29 (m, 8H,
Ar–H). 13C NMR: d 34.2, 96.4, 119.6, 120.1, 124.6, 125.3,
127.1, 131.5, 134.1, 137.3, 140.5, 144.1, 148.3, 163.7, 165.2.
MS m/z (Rel. Int.): 421 (M++1, 3.51), 420 (M+, 17.04), 305
(35.3), 306 (7.2), 293 (8.6), 221 (5.7), 220 (6.7), 195 (12.8),
179 (10.4), 111 (73), 83 (100).
Compound 19: IR (KBr, cm1): 3091 (CH aroma.), 2884,
2855 (CH aliph.), 1685 (C‚O), 1620 (C‚N). 1H NMR: d
4.03 (s, 2H, CH2S), 7.22–8.18 (m, 13H, Ar–H).
13C NMR: d
40.5, 96.2, 124.1, 125.7, 127.5, 129.2, 132.5, 135.1, 138.6,
141.2, 144.0, 149.1, 162.3, 165.4. MS m/z (Rel. Int.): 471
(M++1, 3.11), 470 (M+, 14.97), 289 (75.1), 281 (40.7), 207
(88.3), 73 (100).
2.5. 3-Substituted-2-benzylsulphonyl-6-iodo-3H-quinazolin-4-
one (20, 21)
To a solution of 5 or 7 (0.005 mol) in 50% acetic acid (30 ml),
potassium permanganate (0.8 g, 0.005 mol) in 10 ml water was
added. The reaction mixture was stirred at room temperature
for 2 h. The solvents are removed under reduced pressure
and the obtained solid was ﬁltered, dried and crystallized from
ethanol.
Compound 20: IR (KBr, cm1): 3095 (CH aroma.), 2887,
2835 (CH aliph.), 1675 (C‚O), 1622 (C‚N), 1310, 1150
(SO2).
1H NMR: d 4.38 (s, 2H, CH2N), 4.69 (s, 2H, CH2C6H5),
7.18–8.28 (m, 13H, Ar–H). 13C NMR: d 45.4 (CH2N), 51.1
(CH2C6H5), 96.2, 125.6, 127.5, 128.3, 129.0, 131.5, 135.3,
138.2, 144.5, 145.3, 148.1, 164.0, 165.2. MS m/z (Rel. Int.):
517 (M++1, 5.2), 516 (M+, 22.5), 452 (12.7), 289 (70.4),
287 (66.8), 281 (42.4), 207 (87.3), 73 (100).
Compound 21: IR (KBr, cm1): 3094 (CH aroma.), 2890,
2829 (CH aliph.), 1671 (C‚O), 1622 (C‚N), 1310, 1150
(SO2).
1H NMR: d 4.60 (s, 2H, CH2C6H5), 7.20–8.25 (m,
13H, Ar–H). 13C NMR: d 51.2 (CH2C6H5), 96.7, 124.4,
125.2, 128.5, 131.1, 135.5, 138.0, 145.1, 148.3, 164.0, 166.5.
MS m/z (Rel. Int.): 503 (M++1, 13.7), 502 (M+, 57.9), 438
(5.4), 289 (74.2), 287 (72.5), 281 (40.6), 207 (83.5), 73 (100).
3. Biological testing
3.1. Materials
Doxorubicin vial was a generous gift from the National Can-
cer Institute drug store. The human liver cancer cell line
(HebG2), breast cancer cell line (MCF-7), human cervix carci-
noma cell line (HeLa) and human colon cancer cell line were
obtained from the American Type Culture Collection (Rock-
ville, MD, USA). RPMI medium, Fetal Calf Serum (FCS),
antibiotics for cell culture, trypsin solution and tissue culture
plastic ware were purchased from Costar (Milan, Italy). All
other chemicals were obtained from Sigma Chemical Com-
pany (St. Louis, MO, USA).
3.2. Evaluation of cellular cytotoxicity
The cytotoxic activity of the target compounds against MCF-7
cells, HeLa cells, HepG2 cells and HCT-8 cells was determined
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using Sulforhodamine-B assay (Skehan et al., 1990). In brief,
tumor cells were seeded into 96-well microtiter plates at a con-
centration of 5 · 104 cells/well in fresh medium and left to
attach to the plate for 24 h. Cells were then incubated for
48 h in the absence (control) and in the presence of each com-
pound at the noted concentrations (16–62 lg/ml DMF). Fol-
lowing 48-h of exposure to the compounds, cells were ﬁxed
with 50% cold TCA for 1 h, stained for 30 min with 0.4% Sul-
forhodamine-B and then washed with 1% acetic acid. The
plates were then air-dried and the optical density of each well
was measured spectrophotometrically at 564 nm using the
ELISA microplate reader (Meter tech.ª 960, USA). Surviving
fraction for each cell type was performed from which IC50 was
calculated for each compound under investigation. It is worth
to mention that the cytotoxic activity of Doxorubicin, a stan-
dard and well known anticancer drug, against the used cell
lines was performed at the same concentrations of tested com-
pounds and that the ﬁnal concentration of the either the stan-
dard or the compounds under test in DMF did not exceed
0.2%.
4. Results and discussion
4.1. Chemistry
In the present work a series of new compounds were prepared
according to the synthetic strategy depicted in Schemes 1 and
2. 5-Iodo anthranilic acid was allowed to react with allyl, ben-
zyl and phenyl isothiocyanates to produce the 2-mercapto-3-
substituted-6-iodo-3H-quinazolin-4-ones 1a–c adopting re-
ported procedures (Kottke et al., 1977; Stevens et al., 1997).
The 2-mercapto function of 1a–c was then alkylated with
some selected a-halo ketones as well as some alkyl halides to
afford the corresponding S-alkylthioether derivatives 2–19.
Oxidation of the thioether derivatives 17 and 19 using potas-
sium permanganate afforded the corresponding sulfonyl deriv-
atives 20 and 21, respectively (Table 1).
The structure of the synthesized intermediates and ﬁnal
products was conﬁrmed by elemental analyses, IR, 1H NMR,
13C NMR and mass spectral data. In the IR spectra, generally,
a signiﬁcant stretching band, due to the quinazolinone endocy-
clic carbonyl group, was observed around 1677 cm1 in all
compounds. Compounds 2–13 showed an additional strong
band around 1710 due to the ketonic carbonyl. The IR spec-
trum of compounds 20 and 21 exhibited strong band at 1310
and 1150 cm1 due to the sulfonyl group in addition to the
common pattern of the 3H-quinazolin-4-one backbone. In
the 1HNMR spectra, the signal due to the allyl protons, present
at position 2 and/or 3, in compounds 2, 5, 8, 11, 14–16 and 18,
appeared as multiplet around 3.77–4.28 ppm (CH2), 5.0–
5.20 ppm (‚CH2), and 5.88–6.02 ppm (‚CH). In compounds
3, 6, 9, 12, 15–17 and 19–21 containing benzyl group at position
2 and/ or 3, the CH2 protons appeared at around 3.84–
4.34 ppm as singlet. The other aromatic protons were observed
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13: R1=phenyl, R2=NO2.
O
R2O
Br
R2I CO2H
NH2
RNCS
Scheme 1
N
N
O
I R1
SH
N
N
O
I R1
S R2
1a-c
14-19
alkylhalide
14: R1=R2= allyl. 20: R1=R2=benzyl. 
15: R1= allyl, R2= benzyl. 21: R1=phenyl, R2=benzyl.
16: R1= benzyl, R2= allyl.
17: R1=R2=benzyl.
18: R1= phenyl, R2= allyl.
19: R1= phenyl, R2= benzyl.
KMnO4/AcOH
with 17 and 19
N
N
O
I R1
S R2O
O
20,-21
Scheme 2
340 A.M. Alafeefy
in the expected regions at around 7.7 ppm. Mass spectra of tar-
get compounds showed the major fragment in agreement with
their proposed molecular formula.
4.2. Evaluation of cellular cytotoxicity
The cytotoxic activity of the target compounds against MCF-7
cells, HeLa cells, HepG2 cells and HCT-8 cells was determined
using Sulforhodamine-B assay and Doxorubicin as a reference
drug control. Each cell line was incubated with four concentra-
tions (6.0–62.0 lg/ml) for each compound and was used to
create compound concentration versus survival fraction
curves. The response parameter (IC50) was calculated for each
cell line (Table 2). The IC50 value corresponds to the com-
pound’s concentration causing a net 50% loss of initial cells
at the end of the incubation period (48 h). The antitumor drug
discovery screen has been designed to distinguish between
broad-spectrum antitumor compounds and tumor selective
agents (Monks et al., 1991).
It is well documented that Doxorubicin induces its antitu-
mor activity through several mechanisms including inhibition
of topoisomerase II, DNA intercalation, generation of reactive
oxygen species and DNA-single and double strand breaks. In
the current study Doxorubicin resulted in a signiﬁcant and
dose dependent decrease in the surviving fraction of MCF-7,
HeLa, HepG2 and HCT-8 cells with IC50 4.84, 4.09, 4.65
and 5.26 lg/ml, respectively.
4.3. Cytotoxic activity against human breast cancer (MCF-7)
cell line
As shown in Table 1, among the compounds tested for their
cytotoxicity against the human breast cancer cell line (MCF-
7), 12 compounds showed concentration dependent decrease
in surviving fraction with IC50 almost equivalent to or less
than that of Doxorubicin (IC50 = 4.84 lg/ml). Compounds
5, 6, 8, 9, 14, 15 and 16 were the most cytotoxic members of
this group (IC50  3.50 lg/ml) followed by compounds 2, 3,
11, 12 and 17. The remaining compounds were the least cyto-
toxic as they showed high IC50 and away from that of
Doxorubicin.
4.4. Cytotoxic activity against human cervix carcinoma (HeLa)
cell line
Four compounds showed concentration-dependent decrease in
surviving fraction of HeLa cells with IC50 less than that of
Doxorubicin (IC50 = 4.09 lg/ml). Compound 14 was the most
cytotoxic member of this group (IC50 = 3.31 lg/ml) followed
by compounds 15=16 (IC50 = 3.98 lg/ml) then compound
17 (IC50 = 4.30 lg/ml). Compounds 2, 3, 5, 6, 8, 9, 11 and
12 showed moderate cytotoxic activity against HeLa cell line
with IC50 range (4.6–5.19 lg/ml) which is not far from that
of Doxorubicin. The remaining compounds were poorly cyto-
toxic against HeLa cells.
Table 1 Physicochemical data of compounds 2–21.
N
N
O
I R1
S
R2N
N
O
I R1
S
R2
O
N
N
O
I R1
S
R2O
O
14-192-13 20-21
Compound no.a R1 R2 Molecular formula (MW)
2 Allyl H C19H15IN2O2S (462.30)
3 Benzyl H C23H17IN2O2S (512.36)
4 Phenyl H C22H15IN2O2S (498.34)
5 Allyl Br C19H14BrIN2O2S (541.20)
6 Benzyl Br C23H16BrIN2O2S (591.26)
7 Phenyl Br C22H14BrIN2O2S (577.23)
8 Allyl Cl C19H14ClIN2O2S (496.75)
9 Benzyl Cl C23H16ClIN2O2S (546.81)
10 Phenyl Cl C22H14ClIN2O2S (532.78)
11 Allyl NO2 C19H14IN3O4S (507.30)
12 Benzyl NO2 C23H16IN3O4S (557.36)
13 Phenyl NO2 C22H14IN3O4S (543.33)
14 Allyl Allyl C14H13IN2OS (384.24)
15 Allyl Benzyl C18H15IN2OS (434.29)
16 Benzyl Allyl C18H15IN2OS (434.29)
17 Benzyl Benzyl C22H17IN2OS (484.35)
18 Phenyl Allyl C17H13IN2OS (420.27)
19 Phenyl Benzyl C21H15IN2OS (470.33)
20 Benzyl Benzyl C22H17IN2O3S (516.35)
21 Phenyl Benzyl C21H15IN2O3S (502.32)
a The developing solvent system used is CH2Cl2:CH3OH (9.5:0.5) and the crystallization solvent is ethanol.
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4.5. Cytotoxic activity against the human liver cancer (HepG2)
cell line
Among the compounds under test, four showed concentra-
tion-dependent decrease in surviving fraction of HepG2 cells
with IC50 less than that of Doxorubicin (IC50 = 4.65 lg/ml)
(Table 2). Compounds 14 and 9 were the most cytotoxic
agents (IC50 = 3.70 and 4.17 lg/ml, respectively) followed
by compounds 15 and 16 (which showed the same activity
IC50 4.40 lg/ml) then compound 5 (IC50 = 4.72 lg/ml). The
remaining compounds showed weak or very weak cytotoxic-
ity against HepG2 cells.
4.6. Cytotoxic activity against the human colon cancer (HCT-8)
cell line
Among the compounds under test, four showed concentration-
dependent decrease in surviving fraction of HCT-8 cells with
IC50 less than that of Doxorubicin (IC50 = 5.25 lg/ml) (Table
2). Compounds 14, 15, 8 and 16 were more active than the
standard drug (IC50 = 4.0, 4.35, 4.52, 4.78 lg/ml, respectively)
followed by compounds 5 and 3 which showed almost the
same IC50 (6.03 lg/ml). The remaining compounds showed
weak or very weak cytotoxicity against HCT-8 cells.
4.7. Overall effects of tested compounds against the four human
tumor cell lines
It can be generally seen that the target compounds with allyl
and/or benzyl groups at position-3 were more active than those
derivatives with phenyl group at the same position. Electron
withdrawing groups attached to sulfur atom at position-2 were
only used in the present work so as to leave easily and most
probably alkylate the potential nucleophilic targets. The pres-
ent results proved what was expected, compounds bearing an
electron withdrawing group, halogen and/or nitro substituents,
at position-4 of the phenacyl moiety linked to sulfur at posi-
tion-2, generally improved the activity of the tested com-
pounds relative to un-substituted ones.
The results, in Table 2, showed that ﬁve compounds only
(5, 8, 14, 15 and 16) were cytotoxic against the four selected
cell lines used in our experiment with IC50 similar to or higher
than that of Doxorubicin. It seems from our results that the
human breast cancer (MCF-7) cell line is the most sensitive
to the investigated compounds where 12 compounds showed
a potential cytotoxic activity comparable to the standard drug.
Accordingly, our results warrant a detailed mechanistic
study to investigate the possible mechanism whereby these
compounds induce their cytotoxic activity.
5. Conclusion
The present work led to the development of ﬁve promising
antiproliferative agents. The best cytotoxic results were
obtained with compounds bearing allyl and/or benzyl moiety
at positions 2 and/or 3 of the quinazoline nucleus. Also, an
electron withdrawing group at the position-4 of phenacyl
group linked to 2-mercapto-3H-quinazolin-4one, had the best
impact on the activity. Most probably, these active compounds
are expected to work as DNA alkylators and work is going on
to study the exact mechanism behind.
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